All In Biotech

Drug Trial Radar · NCT05967689

A Study of Zipalertinib in Patients With Advanced Non-Small Cell Lung Cancer With Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertions or Other Uncommon Mutation.

An Open-Label, Phase 2b, Global Multicenter Cohort Trial to Assess the Safety and Efficacy of Zipalertinib in Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer With Exon 20 Insertion and Uncommon/Single or Compound Epidermal Growth Factor Receptor Mutations.

Last checked: Nov 20, 2026Latest source record: Oct 6, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 220 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

220

Planned (sponsor's estimate)

Start

Jul 31, 2023

Primary completion

Aug 31, 2028

Study completion Dec 31, 2028

Sponsor

Lead sponsor
Taiho Oncology, Inc.Industry
Sponsor type
Industry
First posted
Aug 1, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to evaluate the safety, efficacy and pharmacokinetics (PK) of zipalertinib in participants with locally advanced or metastatic Non-Small Cell Lung Cancer (NSCLC) harboring EGFR ex20ins mutations and other mutations.

Conditions

  • Advanced or Metastatic NSCLC Harboring Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion (ex20ins) Mutations

Interventions

  • TAS6417Drug

    Oral tablets

  • CYP CocktailDrug

    Single dose of CYP enzyme probe substrates (CYP cocktail) alone prior to the start of zipalertinib dosing and a single dose of CYP cocktail in combination with zipalertinib at steady state.

  • Transporter CocktailDrug

    Single dose of transporter probe substrates (Transporter cocktail) alone prior to the start of zipalertinib dosing and a single dose of Transporter cocktail in combination with zipalertinib at steady state.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Cohorts 1-4: Objective Response Rate (ORR)Time frame: Up to approximately 2 years
  2. Dose Optimization Substudy: ORR as Assessed by Blinded Independent Central Review (BICR)Time frame: Up to approximately 2 years

Locations

80 sites in 12 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham

    Birmingham, Alabama · Withdrawn

  • City of Hope - Duarte

    Duarte, California · Recruiting

  • Beth Israel Deaconess Medical Center

    Boston, Massachusetts · Recruiting

  • Comprehensive Cancer Centers of Nevada - Central Valley - Twain

    Las Vegas, Nevada · Recruiting

  • Memorial Sloan Kettering Cancer Center - Basking Ridge

    Basking Ridge, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center - Monmouth

    Middletown, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center - Bergen

    Montvale, New Jersey · Recruiting

  • Memorial Sloan Kettering Cancer Center - Commack

    Commack, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - Westchester

    Harrison, New York · Recruiting

  • MSK Cancer Center

    Long Island City, New York · Recruiting

  • Memorial Sloan Kettering Cancer Center - Nassau

    Uniondale, New York · Recruiting

  • Gabrail Cancer and Research Center

    Canton, Ohio · Recruiting

  • Zangmeister Cancer Center

    Columbus, Ohio · Withdrawn

  • The Toledo Clinic Cancer Center

    Toledo, Ohio · Withdrawn

  • SCRI Oncology Partners

    Nashville, Tennessee · Withdrawn

  • University of Texas MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Virginia Cancer Specialists

    Fairfax, Virginia · Recruiting

  • IDS Pharmacy

    Milwaukee, Wisconsin · Recruiting

  • Bankstown-Lidcombe Hospital

    Bankstown, New South Wales, Australia · Recruiting

  • Genesis Care North Shore

    Saint Leonards, New South Wales, Australia · Recruiting

  • Joondalup Hospital Pharmacy

    Joondalup, Western Australia, Australia · Withdrawn

  • William Osler Health System - Brampton Civic Hospital

    Brampton, Canada · Recruiting

  • Hopital Nord Laennec

    Saint-Herblain, France · Recruiting

  • Nouvel Hôpital Civil

    Strasbourg, Aslace, France · Withdrawn

  • Centre Leon Berard

    Lyon, Auvergne-Rhône-Alpes, France · Recruiting

  • CHU Caen Normandie

    Caen, Basse-Normandie, France · Recruiting

  • Hopital Ambroise Pare

    Boulogne-Billancourt, Île-de-France Region, France · Recruiting

  • Institut Curie

    Paris, Île-de-France Region, France · Recruiting

  • Centre Hospitalier Universitaire Limoges

    Limoges, Limousin, France · Recruiting

  • Hopital Haut Leveque

    Pessac, New Aquitaine, France · Recruiting

  • Hôpital Nord de Marseille

    Marseille, Provence-Alpes-Côte d'Azur Region, France · Recruiting

  • Uniklinik Dresden

    Dresden, Germany · Recruiting

  • UKGM Studienzentrale

    Giessen, Germany · Recruiting

  • UKR Innere Med II Pneumologie

    Regensburg, Germany · Withdrawn

  • Gesundheit Nordhessen Holding AG

    Kassel, Hassen, Germany · Recruiting

  • Queen Mary Hospital

    Pok Fu Lam, Hong Kong Island, Hong Kong · Recruiting

  • Azienda Socio-Sanitaria Territoriale di Cremona

    Cremona, Italy · Recruiting

  • Istituto di Ricovero e Cura a Carattere Scientifico (IRCCS) - Ospedale San Raffaele

    Milan, Italy · Recruiting

  • Azienda Ospedaliero-Universitaria di Parma

    Parma, Italy · Recruiting

  • Ospedale S. Maria delle Croci

    Ravenna, Italy · Recruiting

Showing 40 of 80 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.